MuSK autoantibodies in myasthenia gravis detected by cell based assay - A multinational study
- Tsonis, A. I.
- Zisimopoulou, P.
- Lazaridis, K.
- Tzartos, J.
- Matsigkou, E.
- Zouvelou, V.
- Mantegazza, R.
- Antozzi, C.
- Andreetta, F.
- Evoli, A.
- Deymeer, F.
- Saruhan-Direskeneli, G.
- Durmus, H.
- Brenner, T.
- Vaknin, A.
- Berrih-Aknin, S.
- Behin, A.
- Sharshar, T.
- De Baets, M.
- Losen, M.
- Martinez-Martinez, P.
- Kleopa, K. A.
- Zamba-Papanicolaou, E.
- Kyriakides, T.
- Kostera-Pruszczyk, A.
- Szczudlik, P.
- Szyluk, B.
- Lavrnic, D.
- Basta, I.
- Peric, S.
- Tallaksen, C.
- Maniaol, A.
- Pons, C. Casasnovas
- Pitha, J.
- Jakubikova, M.
- Hanisch, F.
- Tzartos, S. J.
DOIAbstract
Seronegative myasthenia gravis (MG) presents a serious gap in MG diagnosis and understanding. We applied a cell based assay (CBA) for the detection of muscle specific kinase (MuSK) antibodies undetectable by radioimmunoassay. We tested 633 triple-seronegative MG patients' sera from 13 countries, detecting 13% as positive. MuSK antibodies were found, at significantly lower frequencies, in 1.9% of healthy controls and 5.1% of other neuroimmune disease patients, including multiple sclerosis and neuromyelitis optica. The clinical data of the newly diagnosed MuSK-MG patients are presented. 27% of ocular seronegative patients were MuSK antibody positive. Moreover, 23% had thymic hyperplasia suggesting that thymic abnormalities are more common tha...
Add to ORKG